

Published in final edited form as:

Toxicon. 2008 February ; 51(2): 297–303. doi:10.1016/j.toxicon.2007.10.004.

NEUTRALIZATION OF TWO NORTH AMERICAN CORAL SNAKE VENOMS WITH UNITED STATES AND MEXICAN ANTIVENOMS

Elda E. Sánchez^{1,§}, Juan C. Lopez-Johnston¹, Alexis Rodríguez-Acosta², and John C. Pérez¹

¹Natural Toxins Research Center, 975 W. Avenue B, MSC 158, Texas A&M University-Kingsville, Kingsville, TX 78363, USA

²Instituto de Medicina Tropical, Universidad Central de Venezuela, Apartado 47423, Caracas 1041, Venezuela.

Abstract

Elapid snakes throughout the world are considered very lethal containing neurotoxic venoms that affect the nervous system. When humans are envenomated it is considered a serious medical emergency, and antivenom is the main form of treatment considered, in spite of the fact that some patients may only survive under intensive therapy treatment such as respiratory support. Coral snakes are part of the family Elapidae and envenomations by these snakes are very low (< 2% of total snakebites) in most countries from southeastern United States to Argentina. In the United States there are only two species of coral snakes of medical importance which belong to the *Micrurus* genera: *Micrurus fulvius fulvius* (Eastern coral snake) and *M. tener tener* (Texas coral snake). In 2006, Wyeth pharmaceutical notified customers that the production of the North American Coral Snake Antivenin (NACSA) in the U.S. was discontinued and adequate supplies were available to meet historical needs through the end of October 2008; and therefore, it is of utmost important to consider other antivenoms as alternatives for the treatment of coral snake envenoming. One logical alternative is the coral snake antivenom, Coralmyx, produced by the Mexican company, Bioclon. In order to compare neutralization between NACSA and Coralmyx antivenoms with the North American coral snake venoms, the venom lethal doses (LD₅₀) and antivenom effective doses (ED₅₀) were determined in 18–20 g, female, BALB/c mice. Additionally, venom comparisons were determined through a non reduced SDS-PAGE for *M. f. fulvius*, *M. t. tener* and the Mexican coral snake venom, *M. nigrocinctus nigrocinctus*. Coralmyx antivenom was able to effectively neutralize 3 LD₅₀ doses of all venom from both *M. t. tener* and *M. f. fulvius*, while Wyeth antivenom only neutralized *M. f. fulvius* venom and was not effective in neutralizing 3 LD₅₀ doses of *M. t. tener* venom. Coralmyx is effective in the neutralization of both clinically important coral snake venoms in the U.S.

Keywords

Coral snakes; *Micrurus fulvius fulvius*; *Micrurus tener tener*; venom, antivenom; neutralization, North American Coral Snake Antivenin; Coralmyx

[§]Corresponding Author. Fax: +1 361 593-3798, E-mail address: elda.sanchez@tamuk.edu (E.E. Sánchez).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

The coral snakes are the only Elapids that exist in the Americas and are represented by three genera: *Leptomicrurus*, *Micruroides* and *Micrurus* (Sandner-Montilla, 1985; Pifano et al., 1986; de Brandao Prieto da Silva, 2001). In the United States there exist three coral snakes representing two genera, which are *Micruroides euryxanthus*, *Micrurus tener tener*, and *Micrurus fulvius fulvius*. The latter two are clinically more significant only because the former displays a shy, elusive behavior that rarely comes into contact with humans (Shaw, 1971). Although the venom of the *Micruroides* is less toxic than *Micrurus*, they all present neurotoxic symptoms (McColloguh and Gennaro, 1971; Wingert and Wainschel, 1975; Aird, 1991; Dalo, 1989; Parrish, 1967). The *Micrurus* species can be found from south, eastern Florida westward to east and south Texas; *M. f. fulvius* are found east of the Mississippi river and *M. t. tener* are found west of the Mississippi river (Campbell and Lamar, 2004; Fig. 1). Envenomation by these snakes can cause death due to the alpha neurotoxins that cause muscle paralysis and respiratory arrest due to postsynaptic, nondepolarization blockage at the neuromuscular junction by binding competitively to the acetylcholine receptor (Lee, 1970 and 1972; Pettigrew and Glass, 1985; Vital-Brazil, 1987; Alape-Giron et al, 1996; Rosso et al, 1996; Francis et al., 1997). The current NACSA will no longer be available after October 2008; and therefore, it is important to determine the ability of other coral snake antivenoms to neutralize the toxic effects of the North American coral snake venoms. The Sonoran coral snake (*M. euryxanthus*) was not included in this study since it is a relatively harmless snake and no deaths have ever been attributed to its bite (McCollough and Gennaro, 1963; Parrish and Khan, 1967).

Since coral snake antivenom became available in 1967 (Kitchens and Van Mierop, 1987), no deaths have been reported in the U.S.; however, before coral snake antivenom, the estimated case fatality rate was 10% (Parrish and Khan, 1967; Norris and Dart, 1989; German et al., 2005), and the cause of death was respiratory or cardiovascular failure. The best and most acceptable form of treatment after coral snake envenoming is with the use of antivenom. This study compared the efficacy of the Mexican antivenom, Coralmyx®, and U.S. antivenom, Wyeth's North American Coral Snake Antivenin to neutralize the toxicity effects of *M. t. tener* (Texas coral snake) and *M. f. fulvius* (Eastern coral snake) venom. Ultimately, the purpose of this study is to determine if Coralmyx antivenom is as effective in neutralizing the U.S. coral snake venoms. It is crucial to find a safe and effective antivenom that will replace the current U.S. one, which will no longer be available after October 2008 (Peterson, 2006).

Methods

2.1. Venoms

Two pools of venom from *M. f. fulvius* (Eastern coral snake) were purchased from Biotoxins Incorporated in St. Cloud, FL (Pool I-Lot#: MF/05A; Pool II-Lot#: MF/038.). Each pool contained venom from approximately 60 specimens found in south central Florida. Venom from *M. t. tener* was extracted from coral snakes found in the Houston area (Pool I) and South Texas area (Pool II) at the Natural Toxins Research Center (NTRC) on the average of every two weeks. Each pool contained venom from approximately 10 specimens. The snakes were allowed to bite into a para-film over a 15 mL test tube. The venoms were centrifuged for 5 min at 23°C at 12,800 × g to remove cellular debris. The venom supernatant was then transferred to vials with the proper labels and stored at -90°C until lyophilized.

2.2. Antivenoms

Coralmyl[®] is a polyclonal antivenom (Fab)₂ fragment with an equine origin, and produced by Instituto Bioclon in Mexico using venom from *Micrurus nigrocinctus nigrocinctus* (Black banded coral snake). The North American Coral Snake Antivenin is a polyclonal IgG with an equine origin, and produced by Wyeth[®] located in the United States using venom from *Micrurus fulvius fulvius* (Eastern coral snake).

2.3. Lethal Dose (LD₅₀)

Five groups of eight mice for each venom were housed in cages and observed throughout the quarantine period and experiments. The endpoint of lethality of the mice was determined after 48 hr. The LD₅₀ of the venoms listed in Tables 1 were determined in BALB/c mice. Venoms were dissolved in 0.85% saline at the highest test dose per mouse. Serial dilutions of 1.5 using saline were made to obtain four additional concentrations. All solutions during the experiment were stored at 0° C and warmed to 37°C just before being injected into mice. The lethal toxicity was determined by injecting 0.2 mL of venom (containing dosages ranging between 2.5 to 13.5 µg/mouse for *M. f. fulvius* venoms and dosages ranging from 4.5 to 22.5 µg/mouse for *M. t. tener* venoms) into a tail vein of 18–20 g female BALB/c mice. The injections were administered using a 1-mL syringe fitted with a 30-gauge, 0.5-inch needle. Saline controls were used. The LD₅₀ was calculated by the Spearman-Kärber method for each pool of venom (n=3 ±SD).

2.4. Antivenom efficacy dose (ED₅₀)

Five groups of eight mice were challenged with a mixture of antivenom containing 3 LD₅₀ of venom. Five doses of antivenom were used. Coralmyl and NACSA vials were reconstituted with 5 or 10 mL, respectively with WFI (water for injection) and all subsequent dilutions were made with sterile 0.85% saline. Stock venom solutions were freshly prepared at 0°C before being used. For each group of mice, 3 venom LD₅₀ were mixed with antivenom and incubated at 37°C for 30 min. Each mouse was injected with 0.2 mL (NACSA) or 0.5 mL (Coralmyl) of venom/antivenom freshly mixed and into the tail vein of mice. The mice were observed for 48 hr and the percent survival and ED₅₀ was calculated by the Spearman-Kärber method for both antivenoms (n=3 ±SD).

2.5. Non-reduced SDS PAGE of *Micrurus* venoms

A total of 6 µg of each venom (*M. t. tener* pools I–II, *M. f. fulvius* pools I–II and *M. n. nigrocinctus*) were run non-reduced on a 10–20%Tris-Glycine SDS PAGE (Invitrogen[™]). A XCell SureLock[™] system with Tris-Glycine SDS running buffer (10X) diluted to 1X at a voltage of 130 for 90 min using a Bio-Rad PowerPac[™] Basic was used. SeeBlue Plus2 markers ranging from 3–250 kDa were used as controls.

Results

Venom lethality and antivenom efficacy

The LD₅₀ of two North American coral snakes venoms and ED₅₀ of two commercial antivenoms against the North American coral snakes were determined by intravenous route (Table 1 and Table 2). *Micrurus fulvius fulvius* venom was 3.4 times more toxic than *M. t. tener* venom 0.23 and 0.8 mg/kg, respectively (Table 1). Coralmyl antivenom was able to neutralize both North American coral snake venoms effectively with a mean ED₅₀ of 507.5 and 319 LD₅₀/5 mL vial for *M. f. fulvius* and *M. t. tener*, respectively (Table 2). The NACSA was effective in neutralizing *M. f. fulvius* venom with a mean ED₅₀ of 449 LD₅₀/10 mL vial, but was not effective in neutralizing at least 44 LD₅₀ of *M. t. tener* venom.

Non-reduced SDS PAGE of *Micrurus* venoms

Micrurus tener tener showed approximately 19 bands, *M. f. fulvius* showed 15 bands, and *M. n. nigrocinctus* showed approximately 17 bands (Fig. 2). All protein bands ranged between 150 to 5 kDa. In general, these three *Micrurus* venoms share some common and some different characteristics.

Discussion

Parrish and Khan (1967) reported that bites of the Eastern coral snakes are believed to be more severe than that of the Texas coral snakes, and the lethality doses in our study confirms their findings since the LD₅₀ for *M. f. fulvius* and *M. t. tener* averaged at 0.279 and 0.779 mg/kg, respectively (Table 1). The majority of the symptoms of coral snake envenomation in the United States have been reported as a result of Eastern coral snakes (McCollough and Gennaro, 1963; Kitchens and Van Mierop, 1987; German et al., 2005). Many of these symptoms include local swelling, respiratory arrest, seizures, paresthesias, vomiting, nausea, dizziness, lethargy, ptosis, among others (Ramsey and Klickstein, 1962; Mosely, 1966; McCollough and Gennaro, 1963; Pifano et al., 1986). Morgan et al. (2007) reported that these symptoms maybe isolated to mainly the Eastern coral snake with the exception of paresthesias. These same investigators reported that 37 patients bitten by the Texas coral snake did not develop neurologic symptoms, and many had more local pain and swelling than that reported for the Eastern coral snake envenomations (Morgan et al, 2007). Nonetheless, Eastern coral snake envenomations will still remain an issue in treatment when the NACSA is no longer available. Eastern coral snake venom does produce neurological symptoms that warrant treatment with antivenom.

The manufacturers of the NACSA state that their antivenom, one vial equaling 10 mL, is able to neutralize 250 LD₅₀, which is equivalent to 2 mg of *M. f. fulvius* venom. On the other hand, the manufacturers of Coralymn state that their antivenom, one vial equaling 5 mL, is able to neutralize 450 LD₅₀, which is 5 mg of *M. n. nigrocinctus* venom. In this study using BALB/c mice, NACSA was able to neutralize an average of 449 LD₅₀ of *M. f. fulvius* venom per vial and less than 44 LD₅₀ for *M. t. tener* venom. Coralymn antivenom was able to neutralize an average of 507.5 LD₅₀ of *M. f. fulvius* venom and 319 LD₅₀ of *M. t. tener* venom (Table 2).

In this study, the two North American coral snake venoms showed differences in lethal potency. *Micrurus fulvius fulvius* had an LD₅₀ of 0.268 to 0.291 mg/kg, which is similar to the LD₅₀ of *M. fulvius* venom in other studies (Arce et al., 2003; de Roodt et al., 2004). On the other hand, *M. t. tener* had an LD₅₀ of 0.736 to 0.822 mg/kg, which is similar to the LD₅₀ of the Mexican coral snake venom, *M. n. nigrocinctus* (de Roodt et al., 2004).

Both antivenoms showed different neutralizing efficacy against both species of coral snakes (Table 1 and Table 2). The NACSA was effective against *M. f. fulvius* venom (ED₅₀=10 mL of antivenom neutralizing a mean of 449 LD₅₀ of venom); however the antivenom was not effective in neutralizing 3 LD₅₀ doses of *M. t. tener* venom. At 10 mL, the NACSA was still not capable of neutralizing 44 LD₅₀ of venom (Table 2). On a milligram basis, the NACSA neutralized *M. f. fulvius* effectively (10 mL neutralizing a mean of 2.4 mg and less than 0.76 mg for *M. t. tener* venom). Coralymn antivenom was effective in neutralizing both *M. f. fulvius* and *M. t. tener* venoms. Neutralization was more effective against *M. t. tener* venom on a milligram basis (ED₅₀= 10 mL of antivenom neutralizing a little over 10 mg of venom), while neutralization of *M. f. fulvius* venom was only half as effective (ED₅₀=10 mL of antivenom neutralizing an average of 5.5 mg of venom) (Table 1). However, on an LD₅₀ basis, Coralymn was more effective in neutralizing *M. f. fulvius* venom (10 mL neutralizing a mean of 507.5 LD₅₀ and 319 LD₅₀ for *M. t. tener* venom) (Table 2). As in previous studies

(Consroe et al., 1995; Arce et al., 2003; Sánchez et al., 2003), the more toxic venoms on an LD₅₀ basis are easier to neutralize because less venom is required to administer an LD₅₀; and thus a more logical way to test antivenom efficacy is first protect the mouse with antivenom and then determine the LD₅₀ as previously suggested (Sánchez et al., 2003). The ability of Coralmyx to neutralize the Texas coral snake venom more effectively than the NACSA could be due to the fact that the Texas coral snake and the Mexican black-banded coral snake are more geographically related (Campbell and Lamar, 2004). According to the SDS-PAGE, *M. t. tener* and *M. n. nigrocinctus* venom shared more common bands than *M. n. nigrocinctus* and *M. f. fulvius* venom (Fig. 2). The similarity of *M. n. nigrocinctus* and *M. t. tener* venom profiles is consistent with the ability of Coralmyx to neutralize these venoms effectively.

Until recently, most of the published article pertaining to coral snake neutralization in the USA has been limited to that of the *M. f. fulvius* (Cohen et al., 1968 and 1971; Amuy et al., 1997; de Brandão da Silva et al., 2001; Wisniewski et al., 2003; de Roodt et al., 2004). This present study reveals a lower effectiveness of the NACSA to neutralize the venom of the Texas coral snake, and recent assessments of Texas coral snake bites have questioned the necessity of antivenom administration when bitten by these Texas snakes (Standford et al., 2005; Borys et al., 2005; Morgan et al., 2007). Further studies are needed to completely rule out the need for antivenom in the cases of Texas coral snake bites. Nonetheless, our study shows that the Mexican antivenom, Coralmyx, is effective in neutralizing the Texas coral snake venom in a mouse model; and thus, could be an alternative in treating patients with both Eastern and Texas coral snake envenomations. Unlike the NACSA, Coralmyx is an F(ab')₂ antibody and it less likely to cause adverse reactions such as anaphylaxis in patients (Sutherland, 1977; Dart and McNally, 2001); furthermore, (Fab')₂ antibodies are distributed faster into the tissue of Coralmyx (Chippaux and Goyffon, 1998) and the reconstitution is immediate as opposed to 45 min for NACSA (Table 3) (Kanavage et al., 2006).

The goal of this study was to determine if Coralmyx antivenom was capable in neutralizing the North American coral snake venoms so that the U.S. may have an effective alternative in treating these envenomations when the NACSA will no longer be available. The results not only show that Coralmyx is effective in neutralizing both coral snake venoms tested, but it is more effective in neutralizing *M. t. tener* venom, than the NACSA. Furthermore, Coralmyx is able to neutralize perhaps the most clinically important coral snake venom, *M. f. fulvius*, with a mean of 507.5 LD₅₀ per vial versus 449 LD₅₀ per vial of the North American approved product.

Acknowledgments

This research was supported by Wyeth Laboratory (Grant #460505), Instituto Bioclon (Grant #460506), NTRC at Texas A&M University-Kingsville: NIH/NCRR #1 P40 RR018300-01, NIH/RIMI #5 PMD000216-02, and NIH/SCORE #5 S06 GM008107-29; and grants from FONACIT (G-2005000400), Caracas, Venezuela. We are grateful to Nora Diaz De Leon, NTRC administrative officer for technical assistance, Mark Hockmuller and Lucy Arispe.

References

- Aird SD, da Silva NJ. Comparative enzymatic composition of Brazilian coral snake (*Micrurus*) venoms. Comp. Biochem. Physiol. Part B. 1991; 99:287–294.
- Alape-Giron A, Stiles B, Schmidt J, Giron-Cortés M, Thelestam M, Jornvall H, Bergman T. Characterization of multiple nicotinic acetylcholine receptor-binding proteins and phospholipases A2 from the venom of the coral snake *Micrurus nigrocinctus*. FEBS Lett. 1996; 380:29–32. [PubMed: 8603741]

- Amuy E, Alape-Girón A, Lomonte B, Thelestam M, Gutiérrez JM. Development of immunoassays for determination of circulating venom antigens during envenomations by coral snakes (*Micrurus* species). *Toxicon*. 1997; 35:1605–1616. [PubMed: 9428107]
- Arce V, Rojas E, Ownby CL, Rojas G, Gutiérrez JM. Preclinical assessment of the ability of polyvalent (Crotalinae) and anticoral (Elapidae) antivenoms produced in Costa Rica to neutralize the venoms of North American snakes. *Toxicon*. 2003; 41:851–860. [PubMed: 12782085]
- Borys DJ, Tobleman WR, Stanford RD, Morgan DL. Is antivenin required for all Texas coral snake (*Micrurus fulvius tenere*) envenomation? Abstract: *Clinical Toxicology*. 2005; 43:709.
- Campbell, JA.; Lamar, WW. *The Venomous Reptiles of the Western Hemisphere*. New York: Cornell University Press; 2004.
- Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. *Toxicon*. 1998; 36:823–846. [PubMed: 9663690]
- Cohen P, Dawson JH, Seligmann EB. Cross-neutralization of *Micrurus fulvius fulvius* (Coral snake) venom by anti-micrurus *Carinicauda dumerilii* serum. *Am. J. Trop. Med. Hyg.* 1968; 17:308–310. [PubMed: 4967162]
- Cohen P, Berkeley WH, Seligmann EB. Coral Snake Venoms: In vitro relation of neutralizing and precipitating antibodies. *Am. J. Trop. Med. Hyg.* 1971; 20:646–649. [PubMed: 5568130]
- Consroe P, Egen N, Russell FE, Gerrish K, Smith DC, Sidki A, Landon JT. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. *Am. J. Trop. Med. Hyg.* 1995; 53:507–510. [PubMed: 7485708]
- Dalo N, Perales J, Munoz R, Martinez B, Moussatche H. Neuromuscular blocking activity of a fraction isolated from the coral snake venom. *Toxicon*. 1989; 27:40.
- Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. *Ann. Emerg. Med.* 2001; 37:181–188. [PubMed: 11174237]
- de Brandao Prieto da Silva AR, Yamagushi IK, Morais JF, Higashi HG, Raw I, Ho PL, de Oliveira JS. Cross reactivity of different specific *Micrurus* antivenom sera with homologous and heterologous snake venoms. *Toxicon*. 2001; 39:949–953. [PubMed: 11223083]
- de Roodt AR, Paniagua-Solis JF, Dolab JA, Estévez-Ramírez J, Ramos-Cerrillo B, Litwin S, Dokmetjian JC, Alagón A. Effectiveness of two common antivenoms for North, Central, and South American *Micrurus* envenomations. *J Toxicology*. 2004; 42:171–178.
- Francis BR, da Silva Junior NJ, Seebart C, Casaise Silva LL, Schmidt JJ, Kaiser II. Toxins isolated from the venom of the Brazilian coral snake (*Micrurus frontalis frontalis*) include hemorrhagic type phospholipases A2 and postsynaptic neurotoxins. *Toxicon*. 1997; 35:1193–1203. [PubMed: 9278969]
- German BT, Hack JB, Brewer K, Meggs WJ. Pressure-immobilization of bandages delay toxicity in a porcine model of Eastern coral snake (*Micrurus fulvius fulvius*) envenomation. *Ann. Emerg. Med.* 2005; 45:603–608. [PubMed: 15940092]
- Kanavage AD, Boyer LV, McNally J, Osterhout JJ. Resistance of antivenom proteins to foaming-induced denaturation. *Toxicon*. 2006; 47:445–452. [PubMed: 16499940]
- Kitchens CS, Van Mierop LH. Envenomation by the Eastern coral snake (*Micrurus fulvius fulvius*). *JAMA*. 1987; 258:1615–1618. [PubMed: 3625968]
- Lee CY. Elapid neurotoxins and their mode of action. *Clin. Toxicol.* 1970; 3:457–452. [PubMed: 4328742]
- Lee CY. Chemistry and pharmacology of polypeptide toxins in snake venoms. *Ann. Rev. Pharmacol.* 1972; 12:265–286. [PubMed: 4339019]
- McCollough, MC.; Gennaro, JF. Treatment of venomous snakebite in the United States. In: Minton, SA., editor. *Snake Venoms and Envenomation*. New York: Marcel Dekker; 1971. p. 137-154.
- Morgan DL, Borys DJ, Stanford R, Kjar D, Tobleman W. Texas coral snake (*Micrurus tener*) bites. *Southern Med. Assoc.* 2007; 100:152–156.
- Norris RL, Dart RC. Apparent coral snake envenomation in a patient without visible fang marks. *Am. J. Emerg. Med.* 1989; 7:402–405. [PubMed: 2735987]
- Parrish HM, Khan MS. Bites of coral snakes: report of 11 representative cases. *Am. J. Med. Sci.* 1967; 253:561–568. [PubMed: 4960877]

- Peterson ME. Snake bite: Coral snakes. Clin. Tech. Small Anim. Pract. 2006; 21:183–186. [PubMed: 17265902]
- Pífanio F, Trujillo M, Rodríguez-Acosta A. Sobre el emponzoñamiento producido por las corales ponzoñosas del trópico americano, especialmente en Venezuela. Med. Crit. Ven. 1986; 1:96–101.
- Pittigrew LC, Glass JP. Neurologic complications of a coral snake bite. Neurology. 1985; 35:589–592. [PubMed: 3982652]
- Rosso JP, Vargas-Rosso O, Gutiérrez JM, Rochat H, Bougis PE. Characterization of alpha-neurotoxin and phospholipase A2 activities from *Micrurus* venoms. Determination of the amino acid sequence and receptor-binding ability of the major alpha-neurotoxin from *Micrurus nigrocinctus nigrocinctus*. Eur. J. Biochem. 1996; 238:231–239. [PubMed: 8665942]
- Sánchez EE, Galán JA, Perez JC, Rodríguez-Acosta A, Chase PB, Pérez JC. The efficacy of two antivenoms against the venom of North American snakes. Toxicon. 2003; 41:357–365. [PubMed: 12565759]
- Sandner-Montilla F. La creación de la familia *Micruridae* para las corales de América de la superfamilia *Elapidoidea*. Mem. Cient. Ofidiol. Inst. Ven. Ofidiol. 1985; 8:14–21.
- Shaw, CE. The coral snakes, genera *Micrurus* and *Micruroides*, of the United States and northern Mexico. In: Bucherl, W.; Buckley, EE., editors. Venomous Animals and Their Venoms. San Diego: Academic; 1971. p. 157-172.
- Standford RD, Borys DJ, Morgan DL, Tobleman WR. Red on yellow kill a fellow, but not in Texas: Five-years of Texas coral snake (*Micrurus fulvius tenere*) envenomations. Abstract: Clinical Toxicology. 2005; 43:707.
- Sutherland SK. Serum Reactions. An analysis of commercial antivenoms and the possible role of anticomplementary activity in denovo reactions to antivenoms and antitoxins. Med. J. Aust. 1977; 1:613–615. [PubMed: 327229]
- Vital-Brazil OV. Coral snake venoms: mode of action and pathophysiology of experimental envenomation. Rev. Inst. Med. Trop. Sao Paulo. 1987; 29:119–126. [PubMed: 3324278]
- Wingert WA, Wainschel J. Diagnosis and management of envenomation by poisonous snakes. South. Med. J. 1975; 68:1015–1026. [PubMed: 1099653]
- Wisniewski MS, Hill RE, Havey JM, Bogdan GM, Dart RC. Australian tiger snake (*Notechis scutatus*) and Mexican coral snake (*Micrurus* species) antivenoms prevent death from United States coral snake (*Micrurus fulvius fulvius*) venom in a mouse model. 2003; 41:7–10.
- World Health Organization. WHO Offset Publication. Geneva: World Health Organization; 1981. Progress in the characterization of venoms and standardization of antivenom.



Figure 1.
Geographical distribution of *Micrurus fulvius fulvius* and *M. tener tener*.




Figure 2. Non-reduced SDS PAGE of *Micrurus* venoms. A 10–20% Tris-Glycine gel was used to run 6 µg of *M. t. tener* venoms pools I and II, *M. f. fulvius* venoms pools I and II and *M. n. nigrocinctus* venom. An XCell SureLock™ electrophoresis system with Tris-Glycine SDS running buffer was used. The gel was run at 130V, 90 min on a Bio-Rad PowerPac™ Basic. The markers used were SeeBlue Plus2 (Invitrogen). Mtt: *M. t. tener*, Mff: *M. f. fulvius*, and Mnn: *M. n. nigrocinctus*.

LD₅₀ of North American Coral Snake Venoms and ED₅₀ of Wyeth and Bioclon Antivenom

Table 1

Species	Pool	LD ₅₀ (i.v.) (mg/kg ± SD) ^c	Mean LD ₅₀ for species	NACSA ED ₅₀ (mL/mg±SD) ^d	NACSA Mean ED ₅₀ (mL/mg)	NACSA ED ₅₀ (mL/mg±SD) ^e	Coralmyn ED ₅₀ (mL/mg ± SD) ^d	Coralmyn Mean ED ₅₀ (mL/mg)
<i>M. f. f.</i>	I ^a	0.268±0.029	0.279	10/2.17± 0.4	10/2.39	1/0.217 ± 0.04	1/0.486 ± 0.071	10/5.5
<i>M. f. f.</i>	II ^a	0.291±0.055		10/2.61± 0.3		1/0.261 ± 0.03	1/0.611 ± 0.124	
<i>M. t. t.</i>	I ^b	0.822±0.118		<10/±0.76	<10/0.76	< 1/ 0.076	1/1.011 ± 0.172	10/11.17
<i>M. t. t.</i>	II ^b	0.736±0.133	0.779	<10/ 0.76		< 1/ 0.076	1/1.223 ± 0.395	

^a Pooled venom obtained from Biotoxins Inc., St. Cloud, FL.

^b Pooled venom obtained from the NTRC, Kingsville, TX.

^c The LD₅₀ is the concentration of venom (mg/kg body weight) required to kill 50% of the BALB/c mice injected iv with 0.2 or 0.5 mL of the various snake venoms. LD₅₀ was calculated using the Spearman-Kärber method.

^d Expressed as mL of antivenom/mg of venom neutralized; ED₅₀ values were determined against 3 LD₅₀ of venoms. n=3

^e Expressed as the amount of protein (mg) neutralized by 1 mL of antivenom.

Table 2

LD₅₀ per mouse and ED₅₀ per vials

Species	Pool	LD ₅₀ mg/mouse	NACSA ED ₅₀ (mL vial/LD50) ^a	NACSA Mean ED ₅₀ (mL vial/LD ₅₀)	NACSA ED ₅₀ (mL/LD ₅₀) ^b	Coralmyn ED ₅₀ (mL vial/LD ₅₀) ^c	Coralmyn Mean ED ₅₀ (mL vial/LD ₅₀)	Coralmyn ED ₅₀ (mL /LD ₅₀) ^b
<i>M. f. f.</i>	I	0.00509	10/426	10/449	1/42.6	5/477	5/507.5	1/95.4
<i>M. f. f.</i>	II	0.00552	10/472		1/47.2	5/538		1/107.6
<i>M. t. t.</i>	I	0.01561	10/< 44	<10/44	1/<0.44	5/323	5/319	1/64.6
<i>M. t. t.</i>	II	0.01398	10/< 44		1/<0.44	5/315		1/63

^aWyeth's insert states that one 10 mL vial neutralizes 250 LD₅₀ of *M. fulvius* venom.^bExpressed as the number of LD₅₀ neutralized by 1 mL of antivenom.^cBioclon's insert states that one 5 mL vial neutralizes 450 LD₅₀ of *Micrurus* ssp venom.

Table 3

Comparison of NACSA and Coralymn

Characteristics	NACSA	Coralymn
Produced	United States of America	Mexico
Origin	Equine	Equine
Antibody Type	IgG	(Fab') ₂
Molecular Weight	110 kDa	50 kDa
Reconstitution (min)	45 ^a	Immediate ^b
Distribution (h)	>3 ^c	3 ^c
Elimination (h)	>100 ^c	60 ^c
Tissue Affinity	High ^c	Moderate-High ^c
Elimination Route	Immune Tissue ^c	Immune Tissue ^c
Binds Complement	Yes ^c	No ^c
ED ₅₀ ^d	1 vial (10 mL) neutralizes 250 LD ₅₀	1 vial (5 mL) neutralizes 450 LD ₅₀

^aKanavage et al., 2006^bCurrent study^cChippaux and Goyffon, 1998^dManufacture's antivenom insert information